Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARNET Phase 2 study of MORF-057 in moderately to severely active Crohn's disease
2023-508158-24-00Phase 2Authorised
- Sponsor
- Morphic Therapeutic
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 2, randomised, double-blind trial of LY4268989 in Crohn's disease (4 arms), sponsored by Morphic Therapeutic. Primary endpoint: Endoscopic response at Week 14. Planned start Jun 2024; status: authorised.
02
Drugs
LY4268989
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-508158-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508158-24-00.